J&J is developing a second Taris-derived candidate called TAR-210, an intravesical formulation of J&J's FGFR kinase inhibitor Balversa (erdafitinib), and has predicted that peak sales of the two ...
Following after in J&J's Taris-derived pipeline is TAR-210, an intravesical formulation of J&J's FGFR kinase inhibitor Balversa (erdafitinib), which started the phase 3 MoonRISe-1 trial in ...
ESMO 2023: TAR-210 Erdafitinib Intravesical Delivery System in Patients with Non–Muscle-Invasive Bladder Cancer with Select FGFR Alterations: First Safety and Efficacy Results ESMO 2023: SunRISe-1: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback